MLL Antibody (H-10): sc-374392

MLL Antibody (H-10) is a mouse monoclonal IgG2b kappa light chain antibody that detects MLL protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-MLL antibody (H-10) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. MLL protein, also known as mixed lineage leukemia 1, plays a crucial role in regulating gene expression during embryonic and hematopoietic development. MLL functions as a histone methyltransferase, specifically methylating lysine 4 on histone H3, which is a key modification associated with active transcription. This post-translational modification helps establish a transcriptionally permissive chromatin environment, facilitating recruitment of transcriptional machinery and promoting expression of target genes. Dysregulation of MLL and associated pathways can lead to severe consequences, including development of acute myeloid leukemia, highlighting the importance of studying MLL in both normal and pathological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MLL Antibody (H-10) References:

1. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.  |  Shinobu, N., et al. 1999. J Biol Chem. 274: 17003-10. PMID: 10358050
2. Panhandle PCR for cDNA: a rapid method for isolation of MLL fusion transcripts involving unknown partner genes.  |  Megonigal, MD., et al. 2000. Proc Natl Acad Sci U S A. 97: 9597-602. PMID: 10920186
3. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.  |  Luo, RT., et al. 2001. Mol Cell Biol. 21: 5678-87. PMID: 11463848
4. Identification of novel biomarkers for MLL-translocated acute myeloid leukemia.  |  Lagacé, K., et al. 2017. Exp Hematol. 56: 58-63. PMID: 28911906
5. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.  |  Yamagata, K., et al. 2021. Leukemia. 35: 2840-2853. PMID: 33967269
6. Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)-Gene Rearrangements.  |  Tsakaneli, A. and Williams, O. 2021. Front Pharmacol. 12: 741413. PMID: 34594227
7. Structural basis for product specificities of MLL family methyltransferases.  |  Li, Y., et al. 2022. Mol Cell. 82: 3810-3825.e8. PMID: 36108631
8. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.  |  Thirman, MJ., et al. 1994. Proc Natl Acad Sci U S A. 91: 12110-4. PMID: 7991593
9. The human ALL-1/MLL/HRX antigen is predominantly localized in the nucleus of resting and proliferating peripheral blood mononuclear cells.  |  Ennas, MG., et al. 1997. Cancer Res. 57: 2035-41. PMID: 9158002
10. Structure and function of RNA polymerase II elongation factor ELL. Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex.  |  Shilatifard, A., et al. 1997. J Biol Chem. 272: 22355-63. PMID: 9268387
11. Overexpression of the MEN/ELL protein, an RNA polymerase II elongation factor, results in transformation of Rat1 cells with dependence on the lysine-rich region.  |  Kanda, Y., et al. 1998. J Biol Chem. 273: 5248-52. PMID: 9478981
12. Factors regulating the transcriptional elongation activity of RNA polymerase II.  |  Shilatifard, A. 1998. FASEB J. 12: 1437-46. PMID: 9806752

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-MLL Antibody (H-10) has 9 citations in a variety of scientific publications.

Primary antibodies like Anti-MLL Antibody (H-10) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

MLL Antibody (H-10) Specifications

Alternate Product Name: KMT2A

Product Clone Name: H-10

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 3351-3389

Epitope Target: MLL

Epitope Species: human

Product Reactivity/Detection: MLL

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 9 citations in various scientific publications

Available Conjugates/Forms for MLL Antibody (H-10): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin